Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Fluoride nanoparticles could hold promise in treating Alzheimer’s

By Brian Buntz | July 14, 2022

Beta amyloid plaque

Beta amyloid plaques. [Image courtesy of NIH]

An international team of researchers has identified a technique that uses fluoride nanoparticles to potentially eliminate protein deformations. The method, which also can promote positive structural changes, could lead to the prevention and treatment of Alzheimer’s disease.

The scientists from Tokyo University of Science (TUS) in Japan and Nazarbayev University in Kazakhstan published the research in ACS Applied Bio Materials.

Noting the amyloid fibrils formed with the self-assembly of denatured proteins are associated with Alzheimer’s disease, the researchers discovered that fluoride nanoparticles could alter the assembly and structure of the amyloid β protein.

Fluoride nanoparticles are used in in vivo imaging, including brain imaging applications.

In particular, the scientists reported the influence of fluoride nanoparticles and surrounding ions on the development of β-sheet structure in amyloid β proteins.

Aberrations in the protein secondary structures or assembly are associated with neurodegenerative diseases, including Alzheimer’s.

The ACS Applied Bio Materials study used a solution of fluoride ceramic (CeF3) nanoparticles to investigate a section of amyloid β peptide.

Using Fourier transform infrared spectroscopy, the scientists discovered that peptides close to the nanoparticle surface were more likely to form β-sheets.

Figure 1

[Image courtesy of Tokyo University of Science]

The researchers also analyzed the use of other surrounding ions in the solution. “What we found was very surprising. Even without the nanoparticles, the environment affected the rate of secondary structure formation,” said Masakazu Umezawa, a TUS professor, in a news release. “This effect, resulting from a combination of electrostatic interaction and hydrogen bonding, was exaggerated upon adding nanoparticles.” Umezawa says that the careful selection of ions and nanoparticles can either suppress or promote β-sheet formation. “This implies that the process can be controlled and engineered to eradicate adverse effects,” he added.

The research community has remained divided concerning the etiology of Alzheimer’s disease. The consensus view in recent decades is the so-called amyloid hypothesis, which assumes the buildup of amyloid-β is the primary cause of Alzheimer’s disease. However, many drug candidates targeting the peptide have failed to deliver convincing results in Alzheimer’s patients.


Filed Under: Neurological Disease
Tagged With: Alzheimer's disease, fluoride ceramic, fluoride nanoparticles, Tokyo University of Science
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Cerevance/Merck
Merck forges Alzheimer’s pact with Cerevance
Scholar Rock logo
Scholar Rock sees continued progress with apitegromab in spinal muscular atrophy
Beacon Biosignals
How EEG data and machine learning can inform drug development
depression
The pandemic is fueling the demand for natural alternatives to antidepressants

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50